SLXN — Silexion Therapeutics Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2022416 ·
Last close
$0.26
Market Cap
$1.45M
52W High
$42.60
52W Low
$0.24
ADV30
8,916,820
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,680,000 | -3,551,000 | 4,246,000 | 2,229,000 | 4,202,000 |
| Mar 2026 | 0 | — | -2,749,000 | -2,733,000 | 4,602,000 | 2,413,000 | 4,311,000 |
| Dec 2025 | 0 | — | -4,406,000 | -4,412,000 | 7,215,000 | 5,991,000 | 4,612,000 |
| Sep 2025 | 0 | — | -3,292,000 | -3,262,000 | 11,614,000 | 9,243,000 | 4,637,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,012,000
Investing CF
$-8,000
Financing CF
$8,291,000
CapEx
$-9,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-33.10
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-57,899,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-12,913,000
Pretax Income TTM
$-12,907,000
Interest Exp TTM
$19,000
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,632,000 | -11,912,000 | 7,215,000 | 4,612,000 | 2,603,000 | -10,819,000 |
| Dec 2024 | 0 | -12,571,000 | -16,443,000 | 2,863,000 | 6,852,000 | -3,989,000 | -8,396,000 |
| Dec 2023 | 0 | -4,681,000 | -4,942,000 | 5,256,000 | 17,312,000 | -15,476,000 | -4,529,000 |
| Dec 2022 | 0 | -3,860,000 | -3,215,000 | 9,333,000 | 16,412,000 | -10,665,000 | -3,335,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.64
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SCNI | Scinai Immunotherapeutics Ltd. | $1.05M | $1.55 | — |
| CRIS | CURIS INC | $2.01M | $0.83 | — |
| ABPO | Abpro Holdings, Inc. | $2.42M | $0.41 | — |
| BCAB | BioAtla, Inc. | $2.47M | $1.48 | — |
| AGTX | Agentix Corp. | $801.3K | $0.02 | — |
News headlines (Yahoo Finance, 1h cache)
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
2026-09-28 12:30 · Yahoo
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
2026-09-09 13:00 · Yahoo
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-14 12:45 · Yahoo
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
2026-08-04 13:15 · Yahoo
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
2026-07-29 11:00 · Yahoo
Silexion Therapeutics to Attend BIO International Convention 2026
2026-06-16 20:30 · Yahoo
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
2026-05-26 12:30 · Yahoo
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-18 12:30 · Yahoo
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
2026-05-15 12:27 · Yahoo
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
2026-05-14 13:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.